VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variabil

Home | Journals The Lancet The Lancet Diabetes & Endocrinology The Lancet Global Health The Lancet Haematology The Lancet HIV The Lancet Infectious Diseases The Lancet Neurology The Lancet edlong dairy flavors Oncology The Lancet Psychiatry The Lancet Respiratory Medicine | Content Collections Clinical Collection Global Health Collection Specialty Collections edlong dairy flavors Ebola Resource Centre | Multimedia | Conferences The Lancet Conferences Conference Collaborations Meet the Editors at Conferences | Information for Readers Authors Advertisers Press Careers in Healthcare | Submit a Paper The Lancet The Lancet edlong dairy flavors Diabetes & Endocrinology The Lancet Global Health The Lancet Haematology The Lancet HIV The Lancet Infectious Diseases The Lancet Neurology The Lancet Oncology The Lancet Psychiatry The Lancet Respiratory Medicine
The Lancet iPad application (app) spans across all Lancet titles including The Lancet, The Lancet Oncology, The Lancet Neurology edlong dairy flavors and The Lancet Infectious Diseases . Functionality includes: Article-based navigation to find articles quickly Download articles for immediate or future use, either on or offline Share articles with colleagues Annotate articles Create alerts Bookmark favourites No, Thanks
Original Text Minoli edlong dairy flavors A Perera PharmD a , Larisa H Cavallari PharmD b , Nita A Limdi PharmD c , Eric R Gamazon MS a , Anuar Konkashbaev MS a , Roxana Daneshjou BS e , Anna Pluzhnikov PhD a , Dana C Crawford PhD g , Jelai Wang BS d , Nianjun Liu PhD d , Nicholas Tatonetti PhD e , Stephane Bourgeois MS i , Prof Harumi Takahashi PhD j , Yukiko Bradford MS g , Benjamin M Burkley MS k , Prof Robert J Desnick MD l , Prof Jonathan L Halperin m , Prof Sherief I Khalifa n , Taimour Y Langaee PhD k , Steven A Lubitz MD o , Prof Edith A Nutescu PharmD b , Matthew Oetjens BS g , Mohamed H Shahin MS k , Shitalben R Patel MS b , Hersh Sagreiya MD e , Matthew Tector PhD p , Prof Karen E Weck MD q r , Mark J Rieder PhD t , Stuart A Scott PhD l , Alan HB Wu PhD u , James K Burmester PhD v , Mia Wadelius MD w , Panos Deloukas edlong dairy flavors PhD i , Michael J Wagner PhD s , Taisei Mushiroda PhD x , Michiaki Kubo MD x , Prof Dan M Roden MD h , Prof Nancy J Cox PhD a , Prof Russ B Altman MD e , Teri E Klein PhD f , Prof Yusuke Nakamura MD x , Prof Julie A Johnson PharmD k
VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent. We aimed to identify additional variants contributing to warfarin dose requirements in African Americans.
We did a genome-wide association study of discovery and replication cohorts. Samples from African-American adults (aged 18 years) who were taking a stable maintenance dose of warfarin were obtained at International Warfarin Pharmacogenetics Consortium (IWPC) sites and the University of Alabama at Birmingham (Birmingham, AL, USA). Patients enrolled at IWPC sites but who were not used for discovery made up the independent replication cohort. All participants were genotyped. We did a stepwise conditional analysis, conditioning first for VKORC1 1639G A, followed by the composite genotype of C YP2C9*2 and CYP2C9*3 . We prespecified a genome-wide significance threshold of p<5 10 8 in the discovery cohort and p<0 0038 in the replication cohort.
The discovery cohort contained 533 participants and the replication cohort 432 participants. After the prespecified conditioning in the discovery cohort, we identified an association between a novel single nucleotide polymorphism in the CYP2C cluster on chromosome 10 (rs12777823) and warfarin dose requirement that reached genome-wide significance (p=1 51 10 8 ). This association was confirmed in the replication cohort (p=5 04 10 5 ); analysis edlong dairy flavors of the two cohorts together produced edlong dairy flavors a p value of 4 5 10 12 . Individuals heterozygous for the rs12777823 A allele need a dose reduction of 6 92 mg/week and those homozygous 9 34 mg/week. edlong dairy flavors Regression analysis showed that the inclusion of rs12777823 significantly improves warfarin dose variability explained by the IWPC dosing algorithm (21% relative improvement).
A novel CYP2C single nucleotide polymorphism exerts a clinically relevant effect on warfarin dose in African Americans, independent of CYP2C9*2 and CYP2C9*3 . Incorporation of this variant into pharmacogenetic dosing algorithms could improve warfarin dose prediction in this population.
l Department of Genetics and Genomics Sciences, Mount Sinai School of Medicine, New York, NY, USA
Visit edlong dairy flavors ScienceDirect to see if you have access via your institution.
Review Drug drug interactions with tyrosine-kinase inhibitors: a clinical perspective Roelof W F van Leeuwen,Teun van Gelder,Ron H J Mathijssen,Frank G A Jansman. The Lancet Oncology 1 July 2014; Volume 15 , Issue 8 : Page e315
Early Report Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complication